PoRaCoat
Innovative stent coating with a polyphenol–rapamycin complex featuring improved drug-release properties for combating restenosis
An innovative stent coating built from a PEDOT matrix with a polyphenol–rapamycin complex, aimed at in-stent restenosis.
The coating should degrade at a controlled rate, release the drug steadily, stay hemo- and cytocompatible, and support endothelial cells while discouraging smooth muscle growth.
[Dłuższy opis projektu do uzupełnienia — cele, zadania, etapy, co już zrobiliśmy.]
Consortium
- Gdańsk University of Technology (Poland)
Coordinator, Polish team lead - Balton Sp. z o.o. (Poland)
Industrial partner - University Hospital Dresden (UKD) (Germany)
Vascular and endovascular surgery - NUST Politehnica Bucharest (Romania)
- Status
- Ongoing
- Started
- since June 2024
- Programme
- M-ERA.NET 3 Call 2023
- Funder
- NCBR (Poland)
- Grant no.
- M-ERA.NET3/2023/92/PoRaCoat/2024
- Funding
- 1 423 392,88 PLN (Polish part)
- Our role
- Coordinator, Polish team lead
- Principal investigator
- Karolina Cysewska
News from this project
Electroactive stent coatings at the Polish Society for Biomaterials conference
An oral presentation on engineering electroactive interfaces on CoCr stents for drug delivery, given at the PSB conference in Rytro.
Three posters at the 47th IMAPS Poland & 18th COE Conference
Drug release from PEDOT films, conductive coatings on stents and ultrathin PEDOT:PSS on PDMS — the lab's contributions to a large showing from the department.
First PoRaCoat results presented at ISE 2026 in Sydney
A talk on depositing PEDOT directly onto commercial cobalt–chromium stents, given at the 77th Annual Meeting of the International Society of Electrochemistry.
PoRaCoat presented at the MaST & MMB Conference
Stent coatings with improved drug release, shown to an audience where research meets industry, together with our partner Balton.


